To Submit your Stock Pick, reply to this Topic following the Standard Layout:
1) Stock Pick
(Ticker & Name of the Company)
2) Reason behind this pick
(a Text with at least 100 words, featuring the reasons of your stock pick)
3) Stock Chart
(Click in additional options, browse for your chart file GIF/JPG/PNG and add it to your post, if you don't have a Charting software, we suggest you copy a chart from www.stockcharts.com)
Important: Do not use this thread to another purpose rather than submitting your stock pick. For organizational purposes, any reply that is not a stock pick will be deleted.
1) Stock Pick: UBET - YouBet.com, Inc
2) Reason behind this pick:
Above both its 50 and 200 days moving averages.
Bouncing off long term upsloping support
Forming an ascending triangle (bullish usually)
Testing 52 week highs
Nearing the APEX of its triangle
In a long term consolidation pattern
Possible Cup & Handle
Most importantly, I OWN THE STOCK! ;D
-------------------------------------------------------------
Earnings - Thursday November 3, 2005
-------------------------------------------------------------
3) Stock Chart:
Time Frame: 2 year
Indicators: Price by volume, MACD, 200 day ma, trendlines, volume
Start: $5.60
Current: $6.30
My stock pick is WZEN.
Based in Seoul, Korea, WEBZEN Inc. has become a global leader in the MMOG market, and has developed some of the world's top online game and client/server technologies. Already having achieved critical mass in Asian markets with publishing arms in Taiwan, China, Japan, Philippines, and Thailand, WEBZEN Inc. has established WEBZEN America, a wholly owned US subsidiary based in Los Angeles. WEBZEN America leverages WEBZEN technology and partners with some of the most well-known names in the video games industry to deliver some of the most compelling, visually stunning graphics available in persistent world games. WEBZEN and WEBZEN America are poised to launch a diverse portfolio of online products and services, beginning with the highly anticipated fantasy MMORPG SUN, the Unreal 3.0 engine-based MMOFPS HUXLEY, and the original action MMOG All Points Bulletin (APB).
It has a very bullish patern.
It's currently trading above the short term, intermediate term and long term EMA's. New highs were reached four times in the last one and a half month. The stock has no MACD alerts.
The chart shows new trendlines setting twice in the last month.
And last but not least I like the Japanese market at the moment. It is very bullish and a lot of money is being invested. I wanted my pick to be Japanese ;).
I do not own the shares. Each time I expected a serious rebound but it did not come...
Amarens
CHK
My pick is a bit larger then most im sure. To go for a win, i will have to stick with this years power house (Energy). I see this stock at high 40s by christmas. It might not double like some of these stocks, but I am sure to see gains out of it.
Chesapeake Energy Corporation engages in the acquisition, development, exploration, production, and marketing of oil and natural gas in the United States. As of December 31, 2004, the company'S estimated proved reserves were 4.9 trillion cubic feet of natural gas equivalent and owned interests in approximately 19,800 producing wells.
This baby has doubled this year and will see much further growth
Many experts say closer to $51
CHK is very well positioned for growth
1) Stock Pick : Komag (KOMG)
2) Reason behind this pick
KOMG has a forward P/E of 7.5. Analysts' opinions for next year's earnings have increased in the last 90 days from $3.39 to $3.59. This kind of value creates a fairly solid base with limited long-term downside risk.
There is currently a negative feel to the entire "moving parts" disk drive sector. The stock dropped on heavy volume prior to earnings, which were outstanding. This gloom and doom attitude provides an excellent buying opportunity. KOMG has 29.82 million shares outstanding, and there are currently 8 million shares short (as of October 11). This is 27%+ of the float, and an increase from 5.3 million shares short in September. With an average volume of 1.6 million, shares are quickly trading hands into those who will hold for the long-term.
KOMG's chart looks terrible, and I expect it might limp along for the next week. However, all this gloom and doom, a low float, solid earnings, and a short ratio of 7.6 sets the stage to surprise the market, the technical analysts, and the shorts. Therefore, I am betting that the pps of KOMG will increase substantially from November-December.
3) Stock Chart : check out the selling pressure lately. I believe this will make a nice "U" over the next month (the duration of the stock picking contest!), breaking the downtrend.
1) Stock Pick
HOM - Home Solutions of America Inc.
2) Reason behind this pick
2.1 Very high growth rate company. Hom grew amazingly in last 2 years on both revenue and income. HOM is also on #2 of IBD highest-rated stocks under $10.
Financial: http://finance.yahoo.com/q/is?s=HOM&annual
IBD: http://biz.yahoo.com/special/low912_05.html
2.2 Expect to have a good earning on Q3, earning out around NOV 14/15.
2.3 During the quarter, they expands disaster remediation infrastructure through acquisition of assets from florida environmental remediation services. They upgraded yearly earning guidance due to the damage from hurricane. We have 3 big hit from hurricane, so HOM should have a lot of work to do.
http://biz.yahoo.com/ap/050929/home_solutions_florida_environmental.html?.v=1
http://biz.yahoo.com/prnews/050929/dath012.html?.v=29
3) Stock Chart
(http://bigcharts.marketwatch.com/charts/big.chart?symb=hom&compidx=aaaaa%3A0&ma=3&maval=50%2C200&uf=8&lf=4&lf2=2&lf3=1&type=4&size=2&state=11&sid=1346433&style=330&time=6&freq=1&comp=NO%5FSYMBOL%5FCHOSEN&nosettings=1&rand=8708&mocktick=1)
Stock pick : NRGY INERGY LP UTS
Reason : Cold weather coming and will be in great demand. Upgraded by Wachovia to outperform.
Inergy, L.P. Declares Increase in Quarterly Distribution
Wednesday October 26, 7:29 am ET
22.4% Year-Over-Year Distribution Increase
KANSAS CITY, Mo.--(BUSINESS WIRE)--Oct. 26, 2005--The Board of Directors of Inergy GP, LLC, managing general partner of Inergy, L.P. (Nasdaq:NRGY - News), today announced an increase in the company's quarterly cash distribution to $0.52 per limited partner unit ($2.08 annually) for the quarter ended September 30, 2005. This represents a 22.4% increase over the same quarter of the prior year, and a 2.0% increase over the distribution for the prior quarter. The distribution will be paid on November 14, 2005, to unitholders of record as of November 7, 2005. The Inergy, L.P. common unit ex-dividend date will be November 3, 2005.
bizjournals.com
Inergy sells N.Y. storage capacity
Wednesday October 26, 4:07 pm ET
Inergy LP said Wednesday that it has sold 100 percent of the capacity of a natural gas storage facility that it bought in July for $230 million.
The Stagecoach facility, based in Tioga County, N.Y., has 13.6 billion cubic feet of natural gas storage capacity. Inergy spokesman Mike Campbell said the company plans to spend $110 million to expand the facility's size by 13 billion cubic feet.
Kansas City-based Inergy (Nasdaq: NRGY - News) has bought rights to nearby natural gas reservoirs and is working through the Federal Energy Regulatory Commission to gain clearance. Construction would begin in 2006, and the expanded capacity would be in service by the fourth quarter of 2007.
Inergy, L.P. also announces updated guidance for the full fiscal year ended September 30, 2006, giving effect to the acquisitions closed to date, including the acquisition of Graeber which we expect to close during the month of October 2005. Inergy expects to generate EBITDA of $169 to $177 million in fiscal year 2006. In addition, Inergy expects to deliver approximately 415 to 435 million retail gallons of propane and generate $416 to $422 million of total gross profit. Below is a table reconciling this anticipated EBITDA to net income:
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Forecast Range ($ in millions) Fiscal Year Ended September 30, 2006
--------------------------------------------------------------------------------
Net Income(a) $ 42 $ 50
Interest Expense(a) (b) 52 52
Depreciation and Amortization(a) 74 74
Income Taxes(a) 1 1
-------------------------------
EBITDA(a) $ 169 $ 177
===============================
Maintenance Capital Expenditures $ 9 $ 8
--------------------------------------------------------------------------------
My pick for this contest would be ACTU.
ACTUATE CORP, (ACTU) provides information delivery solutions for Global 2000 companies, Internet start-ups and packaged application software vendors. The company builds solutions for customer applications including e-CRM, e-Procurement and Net marketplaces.
This pick is mostly based on fundamentals but in a technical view it was trading above $30 in 2001. Recently it delivered good numbers that showed increase in profits.
There have been some accumulation going on among institutonal investors.
Total revenues of $26.8 million increased 13% compared to the third quarter of 2004;
License revenues of $8.9 million increased 11% compared to the third quarter of 2004;
Non-GAAP EPS of $0.06 increased $0.07 compared with the third quarter of 2004;
Repurchased 864,000 shares at a total cost of $2.0 million;
Non-GAAP operating margin was 18%, a record-setting level for the second consecutive quarter;
Non-GAAP net profit margin was a record 13%;
Cash flow from operations for the third quarter 2005 was $3.3 million, bringing the 2005 year-to-date total to $8.3 million;
Cash, cash equivalents and short-term investments reached a record $50.8 million;
Services margin continued to improve to a record 68%.
It is trading now sideways in the 2.80-2.90 area but it might close a gap around 2.6. I wouldn´t bet on that though ;)
My pick is SIRI
Sirius Satellite Radio Inc provides satellite radio services to approximately 1.2 million subscribers. The company provides commercial-free music channels comprising pop, rock, country, hip hop, R&B, dance, jazz, classical, latin, sports, news, talk, entertainment, traffic, and weather programs.
I believe that technically and fundamentally this company is pointing much higher. The last four trading days have been parabolic and I expect a pull back, to the 50 MA. Hopfully a pull back happens before Monday not after.
In order to continue its growth and expansion it is to broadcast and sell the SIRIUS service in Canada. Also Sirius is offering two compact inexpensive and user-friendly units for holiday shoppers. They are the easiest and least expensive way for consumers to access SIRIUS content in their car.
They have extended their exclusive relationship with DaimlerChrysler through to September 1, 2012. The agreement includes all Chrysler Group and Mercedes-Benz vehicles as well as Freightliner Trucks. For model year 2006 over 750,000 subscribers are expected to be generated from the Chrysler Group alone. SIRIUS radios are also currently offered in vehicles produced by Audi, BMW, Ford, Infiniti, Lincoln-Mercury, Lexus, Mazda, Mini, Nissan, Porsche, Scion, Toyota, Volkswagen and Volvo.
As of September 30, 2005, SIRIUS had 2,173,920 subscribers. The third quarter subscriber figure reflects net additions of 359,294 subscribers, a 97% increase over the year-ago figure of 181,948 net subscriber additions.
If the company has the fourth quarter which they expect you could see this company taking off very soon. Both long term and short term, I think that Sirius is very undervalued. If the contest went to January I would feel more confident because I think it has some retracement to do.
1) My pick is NABI
2) For the purposes of this contest I am hoping for a bounce off the recent sell off (not until the contest starts though) The failure of NABI's drug candidate while a disaster for the company and shareholders resulted in a panic sell off that I hope may have gone to far. Hopefully in the next month investors will find enough value left in the companies other products to move the pps up percentage wise from the recent lows.
PR about clinical trial failure http://biz.yahoo.com/prnews/051101/nytu109.html?.v=27
NABI's other drug candidates
About NicVAX
NicVAX is Nabi Biopharmaceuticals' novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. The company was recently awarded a $4.1 million grant by the U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, for partial funding of the company's development program for NicVAX.
By the end of 2005, Nabi Biopharmaceuticals intends to announce preliminary safety and immunogenicity results from a Phase IIb clinical study in Europe. These results will define the next clinical development steps for NicVAX. The company will manufacture NicVAX in its own vaccine facility in Boca Raton, Florida.
About Civacir
Civacir is an investigational human polyclonal antibody product that contains antibodies to the hepatitis C virus (HCV). Civacir is being developed for the prevention of hepatitis C after liver transplant.
The National Institutes of Health (NIH) has funded and conducted a Phase I/II clinical trial of Civacir in HCV-positive liver transplant patients at four study sites in the U.S. This randomized, controlled study evaluated the safety of dosing patients with Civacir during and after transplant surgery, the level of HCV-specific antibodies in trial subjects following dosing, liver enzyme levels (a measure of liver damage) and HCV levels in the transplanted livers.
3) NABI Chart
Nanogen is my pick.
It was difficult to narrow down the opportunities to just one, but I believe NGEN has just as good chances of any of my top 5 candidates.
For the last 2 years Nanogen has boosted my portfolio returns nicely in the last weeks of December 2004 and December 2005.
I choose Nanogen based on:
1) The logic that the stock must be at depressed prices, with the hopes of crossing the 200 DMA sometime in the next month.
2) When the Merryl Lynch Nanotechnology index rallies ^NNZ, Nanogen is usually the leader of the group, as it is a "nano pure play".
3) Earnings were release yesterday and revenue was up and the cash position was strong. All you can ask for a highly-speculative company. (must forget about losses - R&D driven)
My pick is CBOU -caribou coffee. Will become starbucks leading competitor. Coffee has become an expensive commodity.
Stock recenlty IPO and now is reversing in trend. This is short and long term winner I believe.
On October 4, 2005, Caribou Coffee Company, Inc. closed its initial public offering of 5,358,000 shares of its common stock with net proceeds to the Company of $67.7 million.
Highlights for the third quarter of 2005 compared to the third quarter of 2004 include:
Total net sales grew 26 percent to $48.8 million
Comparable coffeehouse net sales increased 3.7 percent
Opened 19 company operated coffeehouses and one licensed coffeehouse
Other Sales advanced 153 percent in the quarter
Adjusted EBITDA was $3.2 million
Net loss of $1.2 million, or ($0.08) per share versus a net loss of $0.8 million, or ($0.06) per share.
Balance sheet strengthened with proceeds from IPO
"We are pleased with our third quarter results as we continue to build momentum in the business by accelerating coffeehouse unit expansion, driving comparable coffeehouse sales growth through innovative offerings such as 'Bou Gourmet, and maximizing commercial and licensing opportunities. The proceeds from the IPO will enable us to continue new coffeehouse development and further establish our brand. We are excited about the growth prospects for Caribou Coffee and look forward to the opportunity of maximizing long-term value for all shareholders," stated Michael Coles, Chairman, Chief Executive Officer and President.
1) My stock pick GTW
Gateway Inc
2) Earnings for the quarter were just recently released for GTW (the #3 computer company in the world) with profits of $15.1 million(4 cents/share) on 1.02 billion in revenue(highest quarterly revs of the year so far). During the same quarter last year GTW lost $59 million(-16 cents/share) on 915 million in revenues. Looks like GTW could be getting back up on its feet.
-Gateway Closes Three Major Federal Deals Valued at More Than $20 Million
Gateway Secures Contracts with the Social Security Administration, Department of the Interior and Department of Defense Dependents Schools for Products and Services
10/24/2005 8:01:46 AM
-Gateway Expands Retail Distribution Through Telnor, Baja Mexico's Leading Telephone Company
10/25/2005 8:02:19 AM
-California Highway Patrol Nabs Gateway's Convertible Notebooks(1.7million contract)
Gateway Selected for Its Unmatched Customer Service and Willingness to Meet the Organization's Unique Challenges
10/19/2005 8:02:13 AM
getting some attention:
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=8156;image)
TA:
GTW's long term price action is forming a farily large descending wedge. Might i add that today price action broke out of an ascending triangle with a price target that will break me out of this wedge which would be very bullish. The triangle breakout gives me a target of 3.34 wich also puts me in uncharted territory hopedfully to fill that ugly gap. If volume picks up and some momentum gets goin i think i could see that gap closed especailly with the positive outlook financially for GTW as well as being able to get it at a bargain price.
3) Chart:
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=8171;image)
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=8172;image)
Good luck all contestents!
may the best trader win (or luckiest ;))
-fousc
My pick: AOB
Chart clearly shows ascending trendline and ready to break out at $5.75. Target: $8.00
The company will report earnings sometime this month and with the momentum, I am expecting they will give a good number.
Breakout happened on Friday with highest volume. I wish that the breakout would happen on Monday, not Friday. But I took position on Friday.
First or Last, no guts no glory!
1) Fonar (ticker symbol - fonr)
This pick has a thread which I started a little ways back, may I say a dead thread, for understandable reasons.
Ok, I have been following this stock for about 6 months and have not enjoyed the ride but I have high hopes.
2)Reasons behind the pick;
a) I believe it has bottomed out, at least I hope.
b) Sector choice - first rate - medical
c) Product - MRI machine (Stand up - proprietary technology - only one of its kind with patent behind it)
d) rising institutional accumulation
e) Low debt to Equity ratio
f) sales growth 46% last 12 mo.
34% last 3 yrs
23% last 5 yrs
g) Earnings per share growth improved for last 3 years
h) After the sale of a machine, servicing the units is there best source of revenue
i) I believe earning come out during contest so that might be a make or break.
J) Press releases have been picking up recently along with a bit of upward action in the stock price over the last few days. With movement in the markets maybe it will be seen as an undervalued play.
3)Sorry about the big chart, good luck all.
1) The pick: WGAT Worldgate Communications. WGAT.
2) The story: Like trader567 said, since I can't control the exit, this is likely a crap shoot. In tihs scenario, I'd pick something with a bit of a history, and although my timing isn't ideal since the stock has already begun reversing a serious downtrend and had already gone up over 40% in the last 2 sessions, the stock's recent history tells me there's probably another 100% or more rise to come, and this move will likely take a month to complete. This company designs / manufactures a video phone that is exclusively distributed via. Motorolla. The product is called the Motorola Ojo. You can see / purchase the product here: http://www.amazon.com/gp/product/B00098175K/102-4752902-3713751?v=glance&n=172282&n=507846&s=electronics&v=glance
The stock has broken out with above average volume a downtrend started back in August. The low point was an intraday $1.64, near the 52 week low during last Wednesday's session. Since then the stock had shot up +20% per session each of the last 2 sessions. The reason for this reversal? There has not been any news announcements from the company but a similar move back in December '04 to January '05 where the stock moved from $2 to $6 was simply based on speculation that the Motorolla Ojo would be widely distributed. That had shown to be a bit premature at the time, but I believe now the product is ready for the Christmas shopping season, and this is probably the reason behind the current move. If this turns out to be the case, I can expect the stock will not stop south of $6 and hence a +100% move is in the cards.
3) The Chart:
CYTO is my pick!
Some info from last earnings report (all from
http://biz.yahoo.com/prnews/051102/phw049.html?.v=20)
Company announces receipt of the 2005 Frost & Sullivan Technology Innovation Award for its contributions to the development of novel therapies incorporating PSMA for combating prostate cancer
Company remains on track for filing an investigational new drug application of its lead therapeutic product candidate for the treatment of hormone refractory prostate cancer in the first quarter of 2006
PRINCETON, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Cytogen Corporation (Nasdaq: CYTO - News) today reported its consolidated financial results for the third quarter and nine months ended September 30, 2005.
FINANCIAL HIGHLIGHTS
-- Total revenues for the third quarter of 2005 were $3.6 million
compared to $3.3 million in the third quarter of 2004. For the nine
months ended September 30, 2005, total revenues were $11.7 million
compared to $10.8 million in the same period of 2004.
-- Gross margin for the nine months ended September 30, 2005 improved to
39% compared to 35% for the same period in 2004.
-- Cytogen reported a net loss of $7.8 million, or $0.44 per basic and
diluted share in the third quarter of 2005, compared to $5.6 million,
or $0.36 per basic and diluted share, for the same period in 2004.
For the nine months ended September 30, 2005, total net loss was
$22.2 million, or $1.36 per basic and diluted share, compared to
$14.3 million, or $0.99 per basic and diluted share, in the same
period of 2004. The increase in net loss results primarily from the
implementation of new marketing initiatives and expansion of the
Company's sales force, which was substantially completed in January
2005.
"We believe that we are pursuing the right commercial strategies to increase product sales within their current indications and the right clinical development strategies to realize their full potential," said Michael D. Becker, Cytogen's president and chief executive officer. "Our clinical development initiatives with QUADRAMET in combination with various potentially synergistic agents, PROSTASCINT for monitoring treatment response and image- guided applications, and our pipeline of product candidates targeting prostate-specific membrane antigen (PSMA) are all of great interest to key opinion leaders who see value in these innovative molecules. We look forward to reporting progress with these initiatives in the months ahead."
PRODUCT REVENUE
QUADRAMET
QUADRAMET is Cytogen's flagship product for the relief of pain due to metastatic bone disease arising from prostate, breast, multiple myeloma and other types of cancer. Sales of QUADRAMET were $2.0 million for the quarter ended September 30, 2005 compared to $1.9 million for the same period in 2004. For the nine months ended September 30, 2005, sales of QUADRAMET were $6.2 million compared to $5.4 million in the same period of 2004.
PROSTASCINT
Sales of PROSTASCINT kits, the first and only commercial monoclonal antibody-based agent that targets PSMA to image the extent and spread of prostate cancer, were $1.5 million for the quarter ended September 30, 2005 compared to $1.3 million in the same period of 2004. For the nine month periods ended September 30, 2005 and 2004, sales of PROSTASCINT were $5.3 million each, demonstrating a consistent demand for the product year-over- year.
Cytogen's strategy for increasing product sales is centered on key drivers of long-term growth for both QUADRAMET and PROSTASCINT. For QUADRAMET, these drivers include: (i) distinguishing the physical properties of QUADRAMET from first-generation agents within its class, (ii) empowering and marketing to key prescribing audiences, (iii) broadening palliative use within label beyond prostate cancer to include breast, lung, multiple myeloma, (iv) clinically evaluating the role of QUADRAMET in combination with other commonly used oncology agents, and (v) expanding clinical development to demonstrate the potential tumoricidal versus palliative attributes of QUADRAMET. For PROSTASCINT, these drivers include: (i) improving image quality through fusion technology, (ii) validating the antigen targeted by PROSTASCINT as an independent prognostic factor, (iii) the publication and presentation of outcomes data, (iv) clinical development of image-guided applications including brachytherapy, intensity modulated radiation therapy, surgery, and cryotherapy, and (v) expanding clinical development to demonstrate the potential for PROSTASCINT to both monitor response to cytotoxic therapies and image PSMA expression in other cancers.
COSTS AND EXPENSES
TOTAL OPERATING EXPENSES
Total operating expenses for the quarter ended September 30, 2005 were $11.5 million compared to $8.9 million for the same period in 2004. For the nine months ended September 30, 2005, total operating expenses were $34.2 million compared to $25.2 million in the same period of 2004.
COST OF PRODUCT REVENUE
Cost of product revenue for the quarters ended September 30, 2005 and September 30, 2004 were $2.4 million and $2.2 million, respectively. For the nine months ended September 30, 2005, cost of product revenue was $7.1 million compared to $7.0 million in the same period of 2004, and primarily reflects QUADRAMET and PROSTASCINT manufacturing costs, royalties paid by Cytogen on the Company's product sales, and the amortization of the up-front payment to Berlex in 2003 to reacquire the marketing rights to QUADRAMET.
SG&A EXPENSES
Selling, general and administrative expenses for the quarter ended September 30, 2005 were $6.7 million compared to $5.3 million for the same period in 2004. For the nine months ended September 30, 2005, total selling, general and administrative expenses were $20.5 million compared to $14.1 million in the same period of 2004. The increase in selling, general and administrative expenses is primarily driven by expanded investment for the commercial support of both QUADRAMET and PROSTASCINT, including the implementation of new marketing initiatives and expansion of the Company's sales force, which was substantially completed in January 2005.
R&D EXPENSES
Research and development expenses for the quarter ended September 30, 2005 were $1.7 million compared to $608,000 for the same period in 2004. For the nine months ended September 30, 2005, total research and development expenses were $3.8 million compared to $2.0 million in the same period of 2004. The increase in research and development expenses is primarily driven by new clinical development initiatives for both QUADRAMET and PROSTASCINT and a $500,000 charge in the second quarter of 2005 for a non-cash milestone payment related to the progress of PSMA development programs. In addition, research and development expenses include preclinical development costs associated with the Company's lead therapeutic product candidate incorporating the same 7E11.C5.3 monoclonal antibody utilized in PROSTASCINT linked to a therapeutic payload to deliver lethal doses of radiation to PSMA-expressing cells.
This stock has been beaten down constantly for the last year or so and finally looks to be turning around a little bit. Stock looks to have bottomed with positive macd indications. RSI has been saying this thing has been oversold up till this week. Has a ways to go to get to strong resistance at 6 (it's at 3 now) and if it breaks that it'll quickly fill the gap to 12!... I'll take 400% how about you? I think $6 by Dec. is very possible. The only analyst on this stock upgraded recently to a target of $17 a share so I'm not alone. Plus earnings estimates have been slowly getting better and better. Here are two charts for y'all to chew on.
1) Stock Pick - KKD, Krispy Kreme Donuts
2) Reason behind this pick
This is another stock that has been beaten down recently. We all know the story: too rapid expansion, possible cooked books, SEC investigation, lawsuits, New York Fed inquiry, CEO search, etc, etc. A company still has value, even one as poorly run as Kripsy Kreme. KKD has reached a new all-time low and rebounded a little. Could it be the bottom? Could all the bad news be priced into the stock? What I like most of all about this pick is the time of year. Shoppers are already descending on the malls and shopping centers, picking up Christmas gifts for all their loved ones. And what do shoppers do during those long, grueling, gift searching outings? They stop to rest at one of the eateries. And drink and eat. I believe the fact that all the bad news is probably already in the stock and the fact that sales should pick up going into the Christmas season, makes KKD an excellent speculative play at this time.
1) ENER is my pick.
Energy Conversion Devices, Inc. engages in the invention, engineering, development, and commercialization of materials, products, and production technology in the fields of alternative energy technology and information technology. The company also involves in research and development, and production of proprietary materials and products, as well as in designing and building production machinery. In addition, it offers Photovoltaics, which provides clean energy by converting sunlight into electricity. Further, the company, through a joint venture with Chevron Technology Ventures, provides nickel metal hydride batteries for various applications, including transportation, telecommunication, uninterruptible power supply, military, homeland security, stationary power, and other prismatic battery applications. Energy Conversion was co-founded by Stanford R. Ovshinsky and Iris M. Ovshinsky in 1960. The company is based in Rochester Hills, Michigan.
2) My pick had to be one of the alternative energy companies, and it was a close race between this and ESLR. (ESLR disqualified itself as my pick by doing extremely well friday.)
There is no way around alternative energy, we need it - and now more than ever as the natural rescourses seems to be running out.
ECD is not only relying on solar, but is a well diversified and growing company. I believe it has a really great future.
Looking at the charts, there can not be much doubt about where this is heading, it took a beating in October as did many other stock.
It shall be interesting to see what happens the day after this contest starts on the 7th! ;)
ECD Ovonics to Report First Quarter Fiscal 2006 Financial Results and Hold Conference Call and Webcast on November 8
1. My pick is Ceradyne (CRDN). Nazdaq Small Cap
2. This company develops, manufactures and markets advanced technical ceramic products and components for industrial, defense, consumer and microwave applications. They have developed five new designs to meet a new government requirement for improved body armor for the defense department, all of which have been approved by the government. Other products they manufacture are components for heavy-duty diesel truck engines, crucibles for the photovoltaic cell industry, ceramic radomes for the PAC-3 (Patriot Advanced Capability) and Arrow missile programs, ceramic components for the oil exploration industry, and translucent ceramic orthodontic brackets.
I'm but a "babe in the woods" when it comes to TA. I have a premium service with Success Investor Toolbox. This pick is based on data gathered from this service such as
Phase I score (> 5/x)
MGZacks score (> 3.25)
Market Guide score (> 2.5)
Volatility score (>2.0)
Avg Vol (>100,000 shrs)
And numerous other indicators.
Ceradyne meets or exceeds all of the indicators that I look for.
I am looking forward to reading feedback (on my pick) from you technicians, so I can continue my TA education, which only began in June on 3SOF. ??? :-\
3 Chart from Success Investor Toolbox
1) Stock Pick: DOC - Digital Angel AMEX 2.760
2) Reason behind this pick:
Fundamentals :
Digital Angel Corporation. The Group's principal activities are development and commercialization of proprietary technologies. The Group operates in three segments: ANIMAL APPLICATIONS: segment develops, manufactures and markets radio, electronic and visual identification devices for the companion animal, livestock, laboratory animal, fish and wildlife markets worldwide. WIRELESS AND MONITORING: segment develops and markets advanced technology to gather location and local sensory data and to communicate that data to an operations center. GPS and RADIO COMMUNICATIONS: segment designs, manufacture and distributes intrinsically safe sounders (horn alarms) for industrial use and other electronic components. On 22-Jan-2004, the Group acquired OuterLink Corporation. On 19-Apr-2004 the Group discontinued Medical Systems segment.
News :
an undervalued stock when you see news !!
10/31/2005 8:02:07 AM
Digital Angel Corporation Announces 2005 Third Quarter, Nine-Month Results
Year Over Year Third Quarter Revenues Up 23% and Nine Months Up 31% Animal Applications Up 59% Over Last Year
10/31/2005 9:00:15 AM
DELRAY BEACH, Fla., Oct 31, 2005 (BUSINESS WIRE) -- Applied Digital (ADSX), a leading provider of identification and security technology, announced today that its wholly-owned subsidiary Thermo Life Energy Corp. has been awarded U.S. Patent No. 6,958,443, entitled "Low Power Thermoelectric Generator", by the U.S. Patent and Trademark Office
11/1/2005 7:00:02 AM
DELRAY BEACH, Fla., Nov 01, 2005 (BUSINESS WIRE) -- Applied Digital (ADSX), a leading provider of identification and security technology, today reported financial results for the third-quarter ended September 30, 2005. The Company's consolidated financial results include the balance sheets, operating results and cash flows of its majority-owned subsidiaries, Digital Angel Corporation (DOC) and InfoTech USA, Inc. (IFTH). ...
Technicals :
all indicators are green....
White marabuzu
Close above moving average (50)
+DI crosses over -DI and ADX < 15 -> THE signal...
ROC is positive ND ChaikinOscillator is positive
Ascending triangle breakout (RSI)
MACD is positive
3) Stock Chart:
Time Frame: 10 months
Indicators: Price, MACD, Bollinger bands, 50 day ma, trendlines, volume, RSI
Start: $2.760
Furure : we will see ?? ::)
My Pick: ERI - Emrise Corporation
Website: http://www.emrise.com/
What they do: Emrise Corporation manufactures defense and aerospace electronic components and subsystems, and communications equipment.
How I searched: I have been focused on short term momentum picks but it wasn't always so ;). So I scanned for stocks in the Nasdaq,NYSE,Amex <$3 with an avg volume > 100,000 using stockcharts.com scan engine. Skimming over the yearly charts I plucked the ones I liked onto a list. I looked at their longer term charts(looking for support), looked at their outstanding shares & mkt(looking for a low number) and thats about it.
-----------
Why I picked ERI: The T/A (This is not in order of signifigance)
Chart 1 - On this longterm view of ERI I saw 3 positive technical signs. First the over-lying trend is up. This increases my chances that the stock wil continue to go up because stocks tend to continue in the direction that they are going unless they meet an opposing force(Newton said something like that :D). Secondly I drew that yellow line connecting tops(rejection points) and saw that width(time) to the line was decreasing. Of course I don't consider this that important but wanted to point it out. Thirdly I was most excited about the parabolic nature I think ERI's rise shows. A parabolic function such as x^2 starts rising exponentionally quick and when I connected the bottoms of ERI(blue line) what I see is the initial stages of one before it goes ballistic. Stocks have portrayed this in the past(not a new theory) and I believe ERI has it.
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=8322%3Cbr%20/%3E*%20ERI%2011-04-2005%20001.JPG)
-------------------------
Chart 2 - I think this sorta makes it clearer as to what I'm talkin about up there. This is what I see.
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=8323%3Cbr%20/%3E*%20ERI%2011-04-2005%20002.JPG)
-------------------------
Chart 3 - Now we zoom to 1 year 1 month long. What have we here? William O'Neil would be skipping. Willie is the dude behind the cup and handle pattern(wrote How To Make Money In Stocks). This pattern shows support and can forecast strong upwards movement.
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=8324%3Cbr%20/%3E*%20ERI%2011-04-2005%20003.JPG)
--------------------------
Chart 4 - Zooming in a final time to 6 months long. Well looking at my chart it looks like I wrote down everything there.
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=8325%3Cbr%20/%3E*%20ERI%2011-04-2005%20004.JPG)
-------------------------
So thats all my research into ERI right there. I want everyone to know that in case they are thinking of buying in. I hold no position and do not know if I will play it. I will study it though.
Goodluck to everybody. 8)
1.) Ticker: Company Name:
OSUR Orasure Technologies Inc.
Sector: Healthcare Industry: Medical Equipment & Supplies
2.) Reason behind the pick:
Earnings up last 3 quarters.
Very good looking "Breakout" from the Ascending Triangle (Continuation)Pattern.
Fundamentally, they have several useful oral testing products and quarterly numbers are showing consistent improvement.Recently turned profitable. Lastly, the meeting with the FDA regarding their HIV take-home test may be a catalyst for the next big move.
Looks to be forming a Cup with Handle (Continuation) Pattern.
Support @ $10.79...10.30...9.93
Resistance @ $11.34...11.50...11.78
Recent CandleStick Analysis
Neutral
Technicals
Last Price Quote is:
4.85%above 13-day EMA
11.50%above 50-day EMA
MACD is Bullish
Stochastic is Bullish
RS Rating: 68
Fundamentals
Earnings Expected on Nov 9
Key Data:
Market Cap (M): $499.07
P/E Ratio: 204.11
PEG Ratio: 2.16667
Next Earnings: 11/09/2005
Last Analyst Rating: Hold
The NY Times reported that Federal drug regulators have agreed to consider allowing a OraSure Technologies to sell the first rapid, at-home AIDS test that would make testing for the virus about as easy and accessible as a pregnancy screen. The move could put to rest 18 years of controversy. "If we're going to win the war against AIDS, we need to make HIV testing as easy as pregnancy testing," said Dr. Freya Spielberg, a researcher in the Center for AIDS Research at the University of Washington.
The test, called OraQuick Advance, is made by OraSure Technologies Inc. of Bethlehem, Pa. It is already widely available in health clinics and doctor's offices, and the FDA is considering permitting it to be sold over the counter.
Company Profile:
OraSure Technologies Inc.
220 East First Street
Bethlehem, PA 18015
Phone: 610-882-1820
Fax: 610-814-2937
Web Site: http://www.orasure.com
DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 194
BUSINESS SUMMARY
OraSure Technologies, Inc. engages in the development, manufacture, and marketing of oral specimen collection devices. Its products include Q.E.D. Saliva Alcohol Test and Intercept, a laboratory-based oral fluid drug test; OraSure HIV-1 oral fluid specimen device, a collection device that collects oral fluid to test for antibodies to the HIV-1 virus; OraQuick Rapid HIV-1 antibody test, a point-of-care test to aid in the diagnosis of infection to HIV-1 using a fingerstick and venipuncture whole blood specimen; Toxicology kits for use in testing blood, urine, hair, oral fluid, sweat, and other forensic samples. The company also offers enzyme immunoassay test kits and oral fluid collection devices, which are used to perform risk assessment testing of life insurance applicants and screen for drugs of abuse, nicotine use, and therapeutic drugs, to insurance laboratory clients; OraSure, a set of MICRO-PLATE products to the blood fractionation market for testing of plasma and related products; Cryosurgery for treating various superficial benign skin lesions, including warts, actinic keratoses, seborrheic keratoses, skin tags, age spots, condyloma acuminate, and molluscum; and Histofreezer portable cryosurgical system for cryosurgery. The company sells its products in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is headquartered in Bethlehem, Pennsylvania.
Stock Pick: Avanir Pharmaceuticals - AVN (yep that's right the sleeping dogs of all dogs) ???
I can't do any of the tech analysis that you all provide... but I have followed AVN for years...
They are awaiting FDA decision on a NDA for Neurodex
New CEO was CFO of AGN. He just bought 500,000 shares @ $3 and another PP recently done at $2.60.
Strong institutional support
I also realize it's up 25% since October but I hope by placing it delicately in this contest that indeed it will be the catalyst for it to double by years end.
Earnings for last quarter will come after contest ends but perhaps their will be pre-release excitement.
Avanir Pharmaceuticals
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858-622-5200
Fax: 858-658-7447
Web Site: http://www.avanir.com
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 60
1) Stock Pick
ASTM - Aastrom Biosciences Inc.
Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology.
2) Reason behind this pick
ASTM is a great company with big potential in the near future. Their technology uses a fascinating idea in that it uses a person's own stem cells (from bone marrow) to treat severe bone fractures, vascular diseases, jaw bone reconstruction as well as spine fusion. It has many clinical trials actively going on in both US and in Europe. Soon they will be opening a manufacturing site in Europe and hoping to rake in big bucks. This company has forcasted that news will be released soon (clinical results, IND decision, etc.) With the vote in congress coming in early January and the news releases that are inevitable, this company will soon soar pass every analysts price target of over $4.00. Good luck to everyone!
3) Stock Chart
1. END - Endeavour International Corporation
2. Independent energy company established to find and develop oil and gas reserves in the North Sea. In less than a year, the company has established one of the industry's largest exploration portfolios in the United Kingdom and a base of production assets with exploratory potential in Norway.
During October, Tejas Securities Group, Inc. and Ferris Baker Watts, Incorporated announced that they have initiated stock coverage of Endeavour with a BUY rating.
Shares outstanding as of November 1, 2005 is 75,489,052.
The stock has corrected 2/3 of the rally from June to September and is setting at support of a short term lower trendline. May have little more down move but many technical indicators are at or near oversold levels, suggesting a rally or corrective move up is near.
3. Six month chart:
(http://bigcharts.marketwatch.com/charts/big.chart?symb=end&compidx=aaaaa%3A0&ma=5&maval=9&uf=8&lf=32&lf2=1024&lf3=4&type=4&size=2&state=11&sid=1683313&style=320&time=7&freq=1&comp=NO%5FSYMBOL%5FCHOSEN&nosettings=1&rand=9490&mocktick=1)
I will pick Abraxas Petroleum Corp. (ABP) for the following reasons:
Due to the short term nature of this contest I need a stock with a near term potential trigger event to get it moving. ABP has earnings coming out on Monday (regretably before the open instead of after the close) and the potential for news on drill results. Either of these could move the stock significantly if the news if positive.
Further it is in a sector (oil and gas) that has enough potential volatility to make it a winner.
Finally it has had a lot of upward momentum until recently and could continue its ascent.
Time will tell.
Good luck to all. (sorry but could not get the graph to paste)
Quote from: Rip on November 06, 2005, 01:17:07 AM
I will pick Abraxas Petroleum Corp. (ABP) for the following reasons:
Due to the short term nature of this contest I need a stock with a near term potential trigger event to get it moving. ABP has earnings coming out on Monday (regretably before the open instead of after the close) and the potential for news on drill results. Either of these could move the stock significantly if the news if positive.
Further it is in a sector (oil and gas) that has enough potential volatility to make it a winner.
Finally it has had a lot of upward momentum until recently and could continue its ascent.
Time will tell.
Good luck to all. (sorry but could not get the graph to paste)
Rip, your chart:(http://bigcharts.marketwatch.com/charts/big.chart?symb=abp&compidx=aaaaa%3A0&ma=5&maval=9&uf=8&lf=32&lf2=1024&lf3=4&type=4&size=2&state=11&sid=7650&style=370&time=7&freq=1&comp=NO%5FSYMBOL%5FCHOSEN&nosettings=1&rand=6202&mocktick=1)
Transmeta Corporation TMTA
Sector: Semiconductors
Why TMTA, well for a start I already have an open position on TMTA, and in fact it is a current 3Stocks open trade also, so for those reasons I must think it is going higher!! I like the way the chart is setting up for TMTA, previous quarter results were good and gave TMTA a lot of momentum helping to re-set a downtrend pattern. A period of consolidation on low volume bought the stock back to the middle of the bollinger bands (weekly chart) where in the past 2 weeks it has found support and rallied also coinciding with latest earnings report (due for release Tuesday). I think the market knows this quarter will not reach the levels of revenue from the prior quarter, I believe guidance and direction will set the tone for hopeful continuation, volume will flow one way or the other once Tuesday is done, so we will see.
I have 2 charts: Weekly shows resistance around the $2 level in the form of previous highs and the 200ema, that is a sticky area, removal of that though and $4 zone is open for attack. Volume will be key as usual. Daily chart has TMTA in a flag with indicators trending nicely, close support and less obvious resistance above.
Company Information
Transmeta Corporation. The Group's principal activities are to develop and distribute software-based microprocessors and additional hardware and software technologies for Mobile Internet Computers. These products are portable computing and communication devices that are compatible with PC software. The products also deliver the performance required to run standard PC and Internet applications and also offer long battery life. Crusoe microprocessors have been developed for lightweight notebook computers and wireless Internet access devices and other Internet appliances. The Crusoe microprocessors are suitable for a broad set of existing and emerging end markets where energy efficiency and x86 software compatibility are desirable. The Group's customers include Sharp, Fujitsu, Hewlett-Packard and Uniquest
Hi,
1)
My pick for the contest is GIGM >:D
The reason for picking GIGM is the following:
On Sept. 29 / GigaMedia Limited announced the sale of all of its ownership interest in its land-based music distribution business to Nextbase International Limited, a company organized and existing under the laws of the British Virgin Islands. The sale was in effect immediately. The total sale price for GigaMedia's stake was US$5.15 million. The Company expects to record a one-time gain related to the transaction which will be mostly offset by operating losses in the music distribution business in the third quarter, resulting in a small aggregate net income contribution to GigaMedia of approximately US$130 thousand during the period. The sale will also increase GigaMedia's cash and cash equivalent balances. ''The music retail business was a legacy of the old Giga, a non-core operation,'' explained GigaMedia CEO Arthur Wang. ''The cornerstone of the new Giga is the high-growth online entertainment sector." ''Disposal of the land-based music retail business will free management resources to accelerate core business growth and the pace of strategic acquisitions,'' stated CEO Wang. GigaMedia acquired its 58.58% ownership in the music distribution business in 2002 as part of a diversification strategy of the old management team.
GigaMedia Limited announced on September 8/05 its fifth consecutive quarter of profitability, with second-quarter 2005 consolidated net income of $1.2 million, up 119 percent from the same period of 2004 and an increase of 20 percent over the first quarter of 2005. The increase in the Company's consolidated net profit was driven by strong performance in GigaMedia's entertainment software business, but limited by a loss in the Company's music distribution unit, which faced continuing operating pressures.
''The second quarter was solid: we delivered good earnings growth despite substantial losses in our music distribution business,'' stated Chief Executive Officer Arthur Wang. ''Moreover, we strengthened the foundation of the new GigaMedia: investing in our online entertainment software business, releasing new products and scaling up our platform.'' GigaMedia is a diversified provider of broadband and entertainment services, with headquarters in Taipei, Taiwan. Giga Media is a holding company and through several subsidiaries distributes recorded music, provide broadband Internet access, and develop software for online entertainment services, including online gaming and social networking.
Giga's core retail music business is operated through the subsidiary G-Music Limited, or G-Music. Through G-Music Giga operates Taiwan's two largest music store chains, Rose Records and Tachung Records. As of September 30, 2004, we operated a total of 46 stores. Our estimated market share of the physical retail music distribution industry in Taiwan in 2003 was between 35% and 45%.
IMO GIGM is now be able to focus on the PROFITABLE areas provide broadband Internet access, and develop software for online entertainment services, including online gaming and social networking.
Last earnings:
http://biz.yahoo.com/prnews/050908/hkth001.html?.v=19
Estimated profit for this year is 0.08 $; with the focus on Software development (profit 1.4 Mio $) and Internet access (0.9 Mio $ profit I will estimate 0.16$ for 2006.
From TA point of view, GIGM should be also be positiv, EMA (9) has crossed the EMA (20) & (50); EMA (20) wil corssing EMA(50) soon (1.87 vs.1.88$)
Last GIGM stock price was at the top of the Bollinger Bands.
If somebody would like to give me feedback, please send me a personal message, always appreciated.
May the force be with us
1) my Stock Pick: AVAN - AVANT Immunotherapeutics Inc
AVANT Immunotherapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization vaccines and therapeutics that address various applications, including cardiovascular, viral, and bacterial diseases. The company markets Rotarix for rotavirus infection, and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. Its immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines, including CholeraGarde for cholera, Ty800 for typhoid fever, and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages, which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines, and other food safety and animal health vaccines. The company has product development and licensing agreements with GlaxoSmithKline plc; Pfizer, Inc; DynPort Vaccine Company LLC; and Lohmann Animal Health International. AVANT Immunotherapeutics was organized in 1983 and is based in Needham, Massachusetts.
2) Reason behind this pick:
Avan has broken out of a long descending wedge with much more than average volume, last week it bounced off very strong support, the short and intermediate chart indicators look bullish
3) Stock chart
Stockcharts.com is still down so i had to use Yahoo. :(
(http://img499.imageshack.us/img499/4426/avan0qs.png)
ALTI Has a great up side potential, its in the hot energy sector ( i was always faniciated with hydrogen energy espically now with oil prices gettiing close to hydrogen production prices ) and just broke two long decending trend lines with some white candles.Here are a few charts.
Note: I included an institutional buying selling chart ( thanks for the link elite g ) I can only go a month with it , but from what i can see there was accumulation , and now there is institute selling on the way up . Warning though i am not to sure of this theory ( i will try to post on the stock ideas posts for some information on these charts and their benefit) . They have also recieved a grant with the unlv
Altair Nanotechnologies, University of Nevada Research Foundation and Alternative Energy Consortium Receive $2.5 Million Grant From U.S. Department of Energy
1 November 2005, 1:32pm ET
Altairnano to Receive $750,000 for Development of Solar Hydrogen Generation Cells
Altair Nanotechnologies, Inc. (NASDAQ: ALTI), in collaboration with the University of Nevada Las Vegas Research Foundation (UNLVRF), today announced the consortium has received a $2.5 million Phase III grant award from the U.S. Department of Energy (DOE) for the joint development of solar hydrogen generation cells. Under the terms of the multi-year grant, Altairnano will receive $750,000 for collaborative research and development efforts through its subcontractor agreement with UNLVRF beginning October 1, 2005, and continuing through December 2006.
"This grant award is timely as the rapid development of alternative energy sources is more necessary than ever for the U.S.," commented Altair Nanotechnologies Chief Executive Officer and President, Alan J. Gotcher, Ph.D. "The consortium's two-pronged approach, which supports the National Hydrogen Fuel Initiative, is the joint development of a cell for direct hydrogen production from sunlight and water, along with related vehicle refilling stations. We expect this approach to accelerate the commercialization of alternative energy vehicles and resource utilization throughout the state of Nevada and, in due course, the United States."
Under the terms of the grant, UNLVRF, a non-profit affiliate of UNLV, will lead a team of industrial and technology partners to spearhead multiple research and development projects to drive production and commercialization of solar technology-based hydrogen projects.
CKCM: Click Commerce Inc.
The fundamental reason to suggest this stock is strong earnings growth:
"Total third quarter 2005 revenues were $16.2 million, representing a 130% growth over third quarter 2004 revenue of $7.0 million. On a non-GAAP basis, excluding certain charges as described below, net income was $4.9 million, or $0.40 per share on a diluted basis. This represents an improvement of approximately $3.3 million over Q3 2004's non-GAAP net income of $1.6 million, an increase of 200%. On a GAAP basis, net income was $3.8 million, or $0.31 per share, an improvement of approximately $2.4 million over the third quarter of 2004's net income of $1.4 million, an increase of 176%. The Company's third quarter results represent its ninth consecutive profitable quarter, with a non-GAAP profit margin of 30% in the third quarter. GAAP profit margins were 23% in the third quarter."
I have highlighted triple digit numbers to show that things are very strong on the earning side.
The stock also fits in the general pattern of year end rally. A tech stock with good earnings and still not trading at ultar high earnings multiples. The two factors make it a realtively safer bet.
Technically stock gapped up a lot after earnings on a huge volume. I expect the gap will remain unfilled. And the bullish trend to continue.
One of the best analysis on CKCM could be found on the thread started by Michael
http://www.3stocksonfire.org/trading/index.php?topic=2438.0
A recent chart is as follows
1- AMR Corporation (AMR) Last Trade: 14.38 Trade Time: Nov 4
2- 52wk Range: 7.83 - 14.95
Volume: 3,626,600
Avg Vol (3m): 4,643,270
Market Cap: 2.37B
EPS (ttm): -3.95
HIGHTLIGHTS
RS (Mkt) to X 10/31/2005
1 Box From RS Buy
COMMENTS
[AMR] AMR Corporation (14.38) started a shakeout on the reversal to Xs on 10/04/2005. As of the very latest price (16:02:03), it is trading at $14.380. High is $14.490, Low is $13.900. Since yesterday's close, it is Unchanged at $14.380 .
AMR is trading above its bullish support line . Relative Strength against the Market is on a Sell signal and the Relative Strength chart is in column of X's. Weekly momentum turned positive on 10/07/2005.
AMR Corporation is part of the Aerospace Airline sector which is in Bear Confirmed status at 42 % in a column of O 's. AMR is trading 56% on the overbought side of the ten week trading band, the middle of this trading band is 12.37. This is a mid cap value stock that trades on the New York Stock Exchange and is Optionable at this time.
AMR Corporation shares outstanding are 156.000 million, 30 day trading volume averages 4456163.00
ATRIBUTTES
Positive
Market TWNYSE (46),
HILO (40) BPNYSE (52),
PTNYSE (70),
RSXNYSE (46),
RSPNYSE (54),
BPOPTI (46)
Sector TW (42) PT (58),
RSP (44),
RSX (50),
BP (42),
RSAERO,
Negative
RS Col RSMKT,
RSDWA
RS Sig RSDWA RSMKT
Trend Chart Trend Shakeout
Momentum Weekly (4),
Daily (9),
Monthly (0)
Trading
Band OB (D) 83%,
OB (W) 56%
Share Data
Split Info 06/10/98 - Split 2 for 1.
03/20/2000 - Split 10000 for 4227.
Optionable Yes
Shares Out 156.0 Mil
30 Day Avg Vol 4,456,163
Mkt Cap $2,243.28
Yield 0.00
ROE 18.45
EPS -3.98
Beta 1.67
Moving Avgs. 50 Day 12.16
150 Day 12.37
200 Day 11.55
Momentums
Daily Positive 9 Days 12.99
Wkly Positive 4 Weeks 10.36
Monthly Positive 0 Months 14.22
RESUME
Technical Data
--------------------------------------------------------------------------------
Sector Data
Sector - Aerospace Airline
Bullish Percent - Bear Confirmed at 42% in Os
Positive Trend - Bear Confirmed at 58% in Os
RS Positive - Bear Confirmed at 44% in Os
RS in X's - Bull Correction at 50% in Os
Sector Relative Strength (DWA Sectors)- Sell in Os
Economic Sectors -
Broad - Consumer Cyclical - Bear Confirmed in Os
Sector - Cyclical Goods and Services - Bear Confirmed in Os
Sub Sector - Airlines - Bull Alert in Xs
Stock Data
Technical Attributes: 4 of 5
Trend - Turned Positive on 05/20/2005
RS Mkt - Sell in Xs
RS Peers - Buy in Xs
Pattern- Shakeout on 10/04/2005
Vertical Price Objective - Bearish Price Obj: $5.00
Std Deviation
TRIGGER: Broke TRIPLE TOP after test BSL
3- (http://www.thinkfn.com/forum/files/a_165.png)
Hi All,
My Pick is HPQ.
Recently after looking into the tech market bigwigs and AMD, INTC, IBM earnings and Dell warning, I think HPQ is good technology buy for next 2-3 weeks for 10 - 20% gain from its current levels. Stock is near its 1 year highs. Management has also done remarkable job in turning around the company. They have been successful in the printer market. The company is doing every thing correct for giving spectacular results.
- Dhiraj
1) My pick is Hemispherx Biopharmaceutical (Amex: HEB)
2) The reason for my pick is that I believe the Avian Bird Flu scare is going to be with us throughout the winter, and certainly at least through the next month. As detailed below, HEB is uniquely positioned to offer a solution that increases the effectiveness of both Tamiflu and Relenza, and, more importantly, drastically reduce the dosage required for each drug to be effective.
HEB's Ampligen, a drug that has completed phase III testing for the treatment of Chronic Fatigue Syndrome, has been shown in recent studies to be very effective when used as an adjuvant with both Tamiflu and Relenza:
Ampligen(R) Studies on Combinational Treatments Against Avian Influenza are Extended
Wednesday October 26, 10:22 am ET
Tamiflu Resistant Strains are Reported in Asia
PHILADELPHIA--(BUSINESS WIRE)--Oct. 26, 2005--Hemispherx Biopharma, Inc. (AMEX: HEB - News) has extended a preclinical report conducted by research affiliates of the National Institutes of Health at Utah State University to examine potential therapeutic synergies with more than 10 different drug combinations. The ongoing research is comparing the relative protection conveyed by Tamiflu (oseltamivir, Roche) and Ampligen® (dsRNA, Hemispherx), alone and in combination, against the avian flu virus (H5N1).
True therapeutic synergy is defined by mathematical equations which indicate that the therapeutic effect observed is in fact greater than the expected arithmetic sum of the two drugs working independently, and is referred to by pharmacologists as the "Chou/Talalay" equations developed at Johns Hopkins University. True therapeutic synergy has now been observed in the interaction between Ampligen® and Tamiflu in the inhibition of the Avian influenza virus.
Hemispherx recently reported new data on preclinical studies on double-stranded RNA (dsRNA), including Ampligen®, one of its flagship experimental immunomodulators. These studies suggest a new, and potentially pivotal, role of dsRNA therapeutics in improving the efficacy of the present standards of care in both influenza prevention and treatment of acute disease.
The studies are attracting growing attention with the persistence of H5N1 avian influenza viruses in many Asian countries and their ability to cause fatal infections in humans. Concerns throughout the Region have risen with the discovery of a Tamiflu resistant strain of the virus. NATURE (14 October 2005), a respected science journal, reported that on February 27, 2005 an H5N1 influenza virus, A/Hanoi/30408/2005, was isolated from a 14 year old Vietnamese girl (patient 1) who had received a prophylactic dose of Tamiflu (oseltamivir). Although further investigation is needed, analysis of the isolated virus revealed two disturbing possibilities; that the virus could have been transmitted to the girl from her brother and that the virus was developing a resistance to Tamiflu. Although the findings were based on a single patient, the authors, in their conclusion, recommend the stockpiling of alternatives to Tamiflu. Hemispherx's Ampligen® is emerging as one of the more promising experimental alternatives.
In antimicrobial (antibacterial) therapy, which is the best studied clinical model, synergistic drug combinations may result in curative conditions/outcomes, often not observed when the single drugs are given alone. In the case of avian influenza where global drug supplies are presumptively in very limited supply relative to potential needs, therapeutic synergistic combinations could not only affect the disease outcome, but also the number of individuals able to access therapies. Cell destruction was measured in vitro using different drug combinations.
At present, a narrow window of opportunity (approximately 48 hours) exists for effective utilization of Tamiflu after exposure to influenza. By providing a new mechanism of inhibition of avian flu, (i.e. immunologic/host defensive immune cascades), Ampligen®, an experimental immunotherapeutic, may also afford a new time interval to help combat the influenza virus.
Recently, double-stranded RNA (dsRNA), such as Ampligen®, are also specific inducers of broad-spectrum antiviral/immune response. As noted in the Company's announcement of September 6, 2005, Japanese researchers have also found that dsRNAs increase the effectiveness of influenza vaccine by more than 300% and may also convey "cross-protection ability against variant viruses" (mutated strains of influenza virus).
Hemispherx Biopharma recently disclosed they entered into a collaboration with HollisterStier Laboratories of Spokane, Washington, for the contract manufacturing of Hemispherx's experimental drug, Ampligen®. The achievement of the initial objectives, in combination with the Polymer production facility under construction in New Brunswick, N.J., will enable Hemispherx to significantly increase production capacity.
Ampligen® also recently completed Phase III testing in the chronic disease, Chronic Fatigue Syndrome (CFS).
About Hemispherx Biopharma
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Hemispherx's flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen® and Oragens(TM). Alferon is approved for a category of STD infection, and Ampligen® and Oragens(TM) represent experimental nucleic acids being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS, Hepatitis. Hemispherx's platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has in excess of 140 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen® and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon® do not imply that the product will ever be specifically approved commercially for these other treatment indications.
--------------------------------------------------------------------------------
Contact:
Hemispherx Biopharma, Inc.
Investor Relations
Dianne Will, 518-398-6222
[email protected] www.hemispherx.net
or
Investor:
Investor Relations Group
Erik Lux/ Adam Holdsworth/ John Nesbett
212-825-3210
or
Media:
Investor Relations Group
Janet Vasquez
212-825-3210
--------------------------------------------------------------------------------
Source: Hemispherx Biopharma, Inc.
Most recently, the company reported on the results of using Ampligen as an adjuvant with Relenza:
Studies Continue to Highlight Hemispherx's Ampligen(R) as Broadly Effective Adjuvant to Avian Influenza Treatments
Thursday November 3, 8:30 am ET
Ampligen(R) Demonstrates Strong Therapeutic Synergy with Relenza(R)
PHILADELPHIA--(BUSINESS WIRE)--Nov. 3, 2005--Hemispherx Biopharma, Inc. (AMEX: HEB - News) announces that the NIH supported independent study at the Utah State University has recently completed research that shows Ampligen®, a Hemispherx experimental immunomodulator, demonstrates strong therapeutic synergy with Relenza® (Zanamivir).
In the study, researchers analyzed the effect of a combination of Ampligen® and Zanamivir on an influenza H5N1 infection in MDCK cells as determined by a cytopathic effect inhibition assay. Zanamivir had zero inhibitory activity when given alone (0.0032 microgram per milliliter) against the avian flu virus, however when co-administered with very low doses of Ampligen® (1 microgram per milliliter) it was shown to be 100% inhibitory.
With the threat of an avian influenza pandemic rising and health officials warning that the virus could develop resistance to current flu treatments, the pursuit of a cost-effective and capable adjuvant to existing antivirals and vaccines has become critical. This combination may permit the use of lower dosages and fewer injections of the antivirals and vaccines used to combat avian flu, thereby decreasing the cost of both immunization programs and treatment programs for the full-blown disease.
In antimicrobial (antibacterial) therapy, which is the best-studied clinical model, synergistic drug combinations may result in curative conditions/outcomes, often not observed when the single drugs are given alone. In the case of avian influenza where global drug supplies are presumptively in very limited supply relative to potential needs, therapeutic synergistic combinations could not only affect the disease outcome, but also the number of individuals able to access therapies. Cell destruction was measured in vitro using different drug combinations.
Hemispherx recently announced that true therapeutic synergy had been observed in the interaction between Ampligen® and Tamiflu in the inhibition of the Avian influenza virus. True therapeutic synergy is defined by mathematical equations which indicate that the therapeutic effect observed is in fact greater than the expected arithmetic sum of the two drugs working independently, and is referred to by pharmacologists as the "Chou/Talalay" equations developed at Johns Hopkins University.
In a recently reported study from a vaccine group in Japan, the incorporation of poly I: poly C (dsRNA) into a nasal administration of a killed influenza A preparation converted a poorly immunogenic response into a highly efficacious vaccine in protection of mice from lethal infection from human influenza A.
Hemispherx Biopharma recently disclosed they entered into a collaboration with HollisterStier Laboratories of Spokane, Washington, for the contract manufacturing of Hemispherx's experimental drug, Ampligen®. The achievement of the initial objectives, in combination with the Polymer production facility under construction in New Brunswick, N.J., will enable Hemispherx to significantly increase production capacity.
Ampligen® also recently completed Phase III testing in the chronic disease, Chronic Fatigue Syndrome (CFS).
About Hemispherx Biopharma
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Hemispherx's flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen® and Oragens®. Alferon is approved for a category of STD infection, and Ampligen® and Oragens® represent experimental nucleic acids being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS, and Hepatitis. Hemispherx's platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has in excess of 140 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen® and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon® do not imply that the product will ever be specifically approved commercially for these other treatment indications.
--------------------------------------------------------------------------------
Contact:
Hemispherx Biopharma, Inc.
Dianne Will, 518-398-6222
Investor Relations
[email protected] www.hemispherx.net
or
Investor Contact:
Investor Relations Group
Erik Lux/ Adam Holdsworth/ John Nesbett, 212-825-3210
or
Media Contact:
Investor Relations Group
Janet Vasquez, 212-825-3210
--------------------------------------------------------------------------------
Source: Hemispherx Biopharma, Inc.
In addition to the potential for use of Ampligen as an adjuvant for Avian Flu treatment, investors are anticipating news that the company is requesting the fast tracking of Ampligen's approval for treatment of Chronic Fatigue Syndrome. Any positive news on this front should send the stock much higher.
Now, I realize that the stock has had a great run over the past month, but with the Avian Flu continuing to spread, and with news regarding the fast tracking of Ampligen for treatment of CFS, this stock still has the potential for an extended run.
3) Here is a chart of HEB:
1) Able Energy Inc. (NASDAQ: ABLE)
2) I perfer energy stock in this period. The reason behind is energy price already stable for almost one month around $60/per barrel, I don't think oil price will go down further in the next couple of week. so far there is still 30%-40% refinery in Gulf Of Mexico shutting-off. Consumer will get bigger bill for their heating, cooking and driving. Able Energy is tiny company operating in NJ. He serve and distribute heating oil, biodiesel. last Q company report record sales of $13.1 million, a 59.8% increase over the same period of 2004. This is not bad for a market cap only 24 million company. and stock price drop 50% more from peak 23 along with energy price decline. stock already stable almost one month. it will head north with winter coming, I believe.
3) from point of TA, it is forming triple bottom, and aim to break out resistance @11 (50ma), as chart indicator. if break out happend, first target will be 15. now volume is picking up in the past few days.
My pick is INTEVAC Inc. (IVAC).
It is coming off of 6 month low.Showing strength.The earnings were out last monday .Estimates were .25 cents,actual was .29cents.Last year same quarter earnings were 7 cents.Insider sold(profit taking).Institutional buyers increased their holdings by 7.3%.Trailing p/e is 77.19.Forward p/e is 13.89.Total cash 45.44 millions.Total debt 0.Average vol. 3 months 274571, jumped to 505856 for the last 10 days.
Company is in Computer sector and in the memory devices .Sector p/e is 25.64.Industry p/e is 17.62 and stock fwd. p/e is 13.89.The logic says Industry p/e will sooner or later move towards the sector p/e., and the stock p/e will move towards the industry p/e.If that logic works quick enough we will have a good winning outcome.In the case of this particular company I believe we have fundamantels and T/A.
My my stock pick is QLTI. It is currently priced at 7.20. Based on cash and fundamentals the company is very undervalued. It has suffered recently on concerns of competition, but should rebound nicely in the coming months.
Good luck to all!
My Pick - SINOVAC BIOTECH LTD. (SVA)
Reasons -
1.) Fundamental reasons:
a.) Basically, most people think this is a bird flu play, but these guys (they are a relatively new biotech company based out of Beijing, China) have 3 commerically avaialble vaccines to treat hepatitis and human influenza. They have a SARS vaccines that has passed the preclinical trial stage and is currently in clinical trials, and mind you, this is the ONLY company that is even developing a SARS vaccine...
http://biz.yahoo.com/bw/051027/275490.html?.v=1
b.) The have the backing of the Chinese govt. who have placed enough trust in them to actually fund the entire R&D phase of the development of the human bird flu vaccine...many people do not know that because of a poorly placed PR (which combined this news along with some news about a UBS presentation) when it was released on Sept. 20
http://biz.yahoo.com/bw/050920/205626.html?.v=1
c.) more importantly, the source of this most recent bird flu problem is int the Asian region (China, S>E Asia)...and this company is extremely well placed and well backed (by the Chinese CDC and SFDA and the govt.) to pursue aggresively the development of the vaccine.
d.) Also, their revenues are in a agrowing trend and will kick into high gear next year and onwards with the recent commerical approval of the Anflu human influenza vaccine.
2.) Technical reasons:
a.) The stock has had a good run this past month or so just like many other stocks in the bird flu sector...but right now, it has pulled back well and successfully tested the 50 DMA...this coming week will show us if the right side of the base (resuming uptrend) will happen or not, but my best bet is, it will. the stochastics show extrmely oversold and is ripe for a move back up. Also, another tech. indicator I follow is the Ultimate oscillator...which is once again at the 30 level, and the last time it was there was when the big move up commenced.
One other thing...the highest this stock has ever closed historically was in the $6.50 range (back in March 2004)...this past month or so, it has tested that range once again...and is kinda facing some resistance in that zone...once it breaks that 6-6.50 range and closes above that, we are in for some fireworks with no real upside resistance after that...with all the news about china, bird flu, and flu vaccines in general, I am willing to bet this stock is primed to go higher in the next 1 month and beyond.
3.) Here's a chart (5 month and 2 year) by the way:
good luck!
My pick:
MEMY - also previous 3SOF pick, yeah I know it's not original but my only original idea that I have faith in is on the OTCC , (RFDL.pk , My favorite long and short term stock) anyways im getting off the subject.
Sector - Pharma
Reasons,
1)
In September 2005, Memory Pharmaceuticals completed dosing in a single center, randomized, double-blind, placebo controlled safety and tolerability study of MEM 1003 in 81 Alzheimer's patients. The Company has also completed a Phase 1 clinical trial in 125 healthy volunteers in the United Kingdom to evaluate the potential cardiovascular impact and side effect profile produced by single and multiple doses of MEM 1003. The Company plans to announce results from the safety and tolerability study during the fourth quarter of 2005.
This seems to compare favorably with the timelines of the contest
2) Insider buying - always a good sign
3) I like the concept of a successful Alzheimer's (sp?) drug for the aging baby boomers
4) not as volatile to give back gains made before Dec 7th , since there haven't been any lately and their might not be since the Phase 2 timeline is not completely defined this is of coerce my opinion but I feel the chart supports this.
this is the first time I have posted a chart here I hope it shows up
My pick for the contest is SYNC. I am a technical trader so I do not follow fundamentals. If you look at a 2 year chart you have a cupN handle pattern here, with the base of the cup at 2.50 and the handle hanging out in the 4.50-4.75 area. I am looking for the stock to break the handle in the next month and proceed to my $6.50 target area. The stock has moved up in the past on good volume and decreased in price on low volume. It recently came back and tested the 50 day, and bounced off of it to the upside nicely. Note that the first retracement on the handle was to the 4.00 area, while the last one was to the 4.30 area, so we are losing strength on the pullbacks and preparing for the real launch from the handle.
Not sure on how to post the chart here, but you can find it at:
http://stockcharts.com/def/servlet/SC.web?c=sync
Tatrader
from Silicon
1 My pick: ANLY
2 Has hit multi year lows and started it's trend back up. Volume shows accumulation, recent support in the uptrend. Mostly a technical pick, but I think that the company shows some positives on the firm foundation side - I think the IT industry will only go up from where it stands now in the US.
3 http://stockcharts.com/def/servlet/SC.web?c=ANLY,uu[w,a]daclyyay[dc][pb50!b200!f][vc60][iut!Ub14!La12,26,9]&pref=G
my pick nflx,Market Cap (intraday): 1.48B
Revenue (ttm): 636.85M
Revenue Per Share (ttm): 12.001
Qtrly Revenue Growth (yoy): 23.10%
Gross Profit (ttm): 229.77M
EBITDA (ttm): 29.91M
Net Income Avl to Common (ttm): 9.39M
Diluted EPS (ttm): 0.14
Qtrly Earnings Growth (yoy): -63.30%
Balance Sheet
Total Cash (mrq): 181.89M
Total Cash Per Share (mrq): 3.392
Total Debt (mrq): 0
Total Debt/Equity (mrq): 0
Current Ratio (mrq): 1.943
Book Value Per Share (mrq): 3.311
a name synonymus with mail order renting of dvd's.
Netflix, Inc. operates as an online movie rental subscription service provider in the United States. It provides its subscribers access to a library of movie, television, and other filmed entertainment titles. The company also offers its subscribers with decision support information on each title in its library. As of December 31, 2004, it provided approximately 2,600,000 subscribers access to a library of approximately 35,000 movie, television, and other filmed entertainment titles. Netflix was incorporated in 1997 and is headquartered in Los Gatos, California.
Press Release Source: Netflix, Inc.
Netflix Announces Upcoming Schedule of Events With the Financial Community
Monday October 31, 4:15 pm ET
LOS GATOS, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Netflix, Inc. (Nasdaq: NFLX - News) today announced participation in the following upcoming events with the financial community during the month of November:
Pacific Growth Equities Top Pick in Tech Conference 2005
Tuesday, November 15, 2005
New York, NY
7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time
Presenter: Barry McCarthy, CFO
Lehman Brothers Second Annual Small Cap Conference
Wednesday, November 16, 2005
Carlsbad, CA
10:40 a.m. Pacific Time / 1:40 p.m. Eastern Time
Presenter: Barry McCarthy, CFO
CSFB Annual Technology Conference
Wednesday, November 30, 2005
Scottsdale, AZ
9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time
Presenter: Reed Hastings, CEO and co-founder
nflx, since it's break out on 7/26 hasn't looked back , with a 52 week high of 29.49 , then some pullback in october, ( we all know about october) nflx is positoined to test this, and sail on to new highs
;D chart for nflx
1) SWC - Stillwater Mining Co
Thanks guys for pointing out my last pic (OWENQ) was OTC!
2) I'm picking this one because palladium prices have imploded (approx. from $1K/oz to $200/oz) and are starting to shoot up.
Also, last report was that geological surveys came out very positive (Trend Mining exploration results reported Oct, 31,05)
If the dollar is going to go down, this one should do very well.
"SWC mines, processes and refines palladium, platinum and related metals from a geological formation in southern Montana called the J-M Reef, which is the only major source of platinum group metals outside of South Africa & Russia. For the 6 months ended 6/30/05, revenues rose 37% to $252.8M. Net loss before accounting change totaled $1.8M, vs. an income of $21.4M. Results reflect 3 sales agreements to sell the palladium, offset by higher depreciation."
Recent T/A starting to look bullish
3) Can I get your help one more time with the chart?
http://stockcharts.com/def/servlet/SC.web?c=swc
My pick: VPHM
Reason for pick: Earnings tomorrow on 11/7/05, should beat the numbers. My pick is based on good fundamentals and technicals !
Going into the winter season, this stock should go up !
Some recent news for my pick:
NEW YORK, Nov 3 (Reuters) - Drug maker ViroPharma Inc. (VPHM.O: Quote, Profile, Research) on Thursday said it amended its manufacturing agreement with Eli Lilly and Co. (LLY.N: Quote, Profile, Research) to increase its supply of the antibiotic Vancocin to treat intestinal bacteria.
ViroPharma said it will pay Lilly up to $4.5 million in addition to the original contract price through early 2006.
The Exton, Pennsylvania-based company said its future annual forecast for 2006 will reflect the expanded investment.
ViroPharma, which bought Vancocin from Lilly in December, said Lilly agreed to continue manufacturing the drug at least through Sept. 30, 2006, while ViroPharma transitions to a third-party supply chain.
While the current supply contract was sufficient to meet demand, ViroPharma said it wants to establish a stock inventory of the drug as a precautionary measure in case the incidence and severity of the bacterial infections continue to increase at a higher-than-expected rate.
Vancocin, which had $28.8 million in sales during the second quarter, is used in hospitals to treat staphyloccal enterocolitis and pseudomembranous colitis, bacterial infections that sometimes occur after treatment with antibiotics and cause diarrhea.
Mattel MAT
Heading into the Xmas season, I like the cyclical play (As a dad, I know I'm spending a lot on toys) and this constitutes a value play with a forward PE of 13.7
Technically, I picked MAT beacuse of it's recent bounce off it's 52 week low (Yes the Monday Nov. 7 Buy in price is attractive) and I look for the Gap to be filled based on the Momentum run off the 60 day EMA
(http://img.photobucket.com/albums/v11/kcscott/Mattel.png)
Since this game only runs for this month, someone already picked CKCM, and it's late on Sunday night it was either this or Tyson Foods :P
My stock pick is: SNTO
Charts:
2 year weekly chart
(http://img478.imageshack.us/img478/3313/sntoweek6lf.png)
This chart shows that this stock was up to 17.89 in March. Stock is now at 7.05.
Green trend lines show a top of 12.50. Blue Andrews Pitchfork shows mid-tyne at a little under 15, and top tyne of fork at over 20. Other indicators look good with plenty of room for MACD and ADX +D1 to go up.
Daily chart
(http://img373.imageshack.us/img373/6442/sntod6ql.png)
Nice shart trend up, notice solid green uptrend line and newer green dash uptrend line to take its place. This stock runs with the 9 day ema. Good volume candles. Looks somewhat overbought, but should go higher. Maybe a small pullback, but I expect this to keep trending up.
60-minute Chart
(http://img488.imageshack.us/img488/218/snto600vh.png)
Trend is shown well on this 60 minute chart. Trend line is moving straight up, and Andrew's Pitchfork continuing along. Notice candles falling in line with the bottom of the blue Pitchfork. Plenty of room on the ADX and MACD. Indicators turned up.
Nice volume candles at Friday's close. Normally, stocks don't close strong on a Friday. Perhaps it was shorts closing their positions.
P&F Chart
(http://img457.imageshack.us/img457/1665/sntopnf2cf.png)
what can I say? Bullish price: 14.75
Fundies:
This stock is in a position of having been a loser for over a year, but now it has hit the bottom of the that trend, and is now advancing up.
This stock has all the major ingredients of a stock that is undervalued and has put in good earnings and is in the position of running up real hard.
Listen to their CC: http://biz.yahoo.com/cc/9/61569.html
In case you don't know, this is a call center company.
This has a low float.
They got A+ on accumulation on IBD
They will be hiring 600 people
If you do you will learn that they have 6 new contracts, one is Overstock, one is Lenscrafters, and one is a unknown billion dollar company (my guess, McDonalds, or someone like that, who doesn't want any publicity). There are 3 more to come, and will be announced by PR's.
They were losing money until recently. They had an acquisition and restructing which dropped them down from the last high, but now they are in the money. The company posted 8 cents profit vs. a loss of 15 cents a year ago, and a loss of 44 cents last quarter. They announced they are returning to profitability two quarters earlier than expected. Their gross margins are up 19.9%, an increase of 120% quarter over quarter. No planned acquisitions. Low long term debt and some cash. Guidance was not given, but they said they will make more than .08 next quarter. They expect accelerating earnings going forward.
This stock is a hidden gem. Should really take off.
My stock pick is BMD: Birch Mountain Resources. A small company engages in the exploration of industrial minerals in Canada. It owns approximately 402,965 hectares of mineral property in Athabasca and Birch Mountains, Alberta. The company also engages in the research and development of naturally occurring precious and nonprecious metal microparticles and nanoparticles. Birch Mountain was founded in 1994 and is headquartered in Calgary, Canada. What makes them interesting is they serviceAthabasca oil sands, providing infrastructureto and from the region, thus it is an ancillary play not necessarily tied to the price of oil. The oil-sands of Canada will be developed and its importance will grow exponetially. Technically, the chart is beautiful. Every one to two months it has been hitting new highs, by moving up with a large white candle and then progressively moving higher by 25% to 100%. The last high unitl recently was 5.72 in early October an just last week it has had thre white candles in a row reaching another new high of 5.93 on Friday, the 4th. I expect we will see 6.50 to 7.50 yb early December before the usual flatlining begins.
I have never added a chart before so I I have been reading on how to do it - I dont kno if this will work but I am going to attach a png file below - here goes:
1) My pick is gnbt which is GenerexBiotech Corp in Nasdaq
2) Why do i pick gnbt? Well it is a stock that deals with something that is in the news every day as of late, the possible Avian Bird Flu outbreak. But not only that, it has more products in its pipeline. On of them is Oralin, which is a proprietary insulin formulation used for diabetes management. Its Oralin product is delivered through RapidMist device, which is used to administer large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. It also conducts research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune, and allergic diseases. So the main reason is because it can be a product to be utilized to combat avian flu. Also chart looks like nvax in the early stages. As you remember that stock did like a 4x advance. Also it has been before senators seeking support for the accelerated development of its novel vaccine for H5N1 avian influenza. So it that happens, it hink stock can fly.
3) here is the chart for gnbt
My pick is ORCT (Orckit Communications Ltd)
Orckit is an Israeli company that sells communications equipment internationally. Since transitioning to focus on "Triple Play" communications gear, they've only had 1 main customer, KDDI in Japan, which allows a service provider (i.e., telecomm or cable) to offer voice, data, and video together across networks. Here's a businessweek article discussing how the "Triple Play" is the big trend in the industry: http://yahoo.businessweek.com/investor/content/nov2005/pi2005114_7121_pi044.htm
In July, ORCT fell from over $28 after guiding Q3 EPS to .23 vs. analyst estimates of .25. It broke its uptrend and subsequently drifted down to the 20 area ahead of the Q3 report. On 10/21, it broke 20 support and on 10/24 made a new low at 17.77. After a bounce, on Thursday, 10/27, ORCT broke that new 17.77 support, triggering stops and massive selling. Rumors circulated about them losing their one customer, Israel being attacked by Iran, or them missing EPS badly. On record volume of over 3.5 million shares, ORCT sold down as low as 12.22, $7 below the previous close. In retrospect, that was a climactic, capitulation panic selloff.
On Monday morning, 10/31, ORCT announced blowout earnings of .30 (excluding a one-time capital gain), well above what analysts had predicted before the selloff from over $28. In addition, they mentioned they had begun shipments to a U.S. telecom carrier, though no revenues were included in the Q3 report. Also, they upped Q4 guidance to .41 vs. .33 estimates, resulting in full year guidance of $1.11 (excluding the one-time gain). They upped 2006 guidance to $1.50, more than 35% growth over 2005. On the conference call, they indicated that these numbers were based only on existing customers, and any new customers would be addtional to these estimates. They also hinted at several potential new customers, particularly in Asia. Finally, they announced that they'd paid off all of their debt.
So ORCT dropped from $28+ down to $12.22 after disappointing guidance, and subsequently blew out the original estimates while mentioning a new U.S. customer (not yet formally announced separately nor reflected in earnings) and upping guidance significantly, yet the stock still sits under $22, almost 25% lower than before all of this improvement in fundamentals. The jump from 12.22 back over $20 in just 2 days attracted a large number of shorts. Despite the jump, ORCT has consolidated in the 20-22 area the last week. With the capitulation selloff behind it, many new shorts who will have to cover, and fundamentals pointing to a much higher price, ORCT looks like a tremendous bargain. Even a conservative 30 PE on 2006 earnings for the 35% growth would put ORCT at $45, more than double the current price. Any new customers would increase those numbers. With a recent history of being very conservative on guidance and then blowing out estimates, ORCT has huge upside.
Many analysts from many firms were on the earnings call, but only one (RBC's Daniel Meron) has been covering it. That one had a target of $34 before earnings, and likely will increase that substantially after the large increase in guidance. Other firms should initiate coverage soon after establishing their position.
1) Stock Pick: BOOM (Dynamic Materials Corp.)
2) Reason behind this pick:
We all know that BOOM is growing rapidly, Decreased their debt & mosf of all they will
report their 3Q earnings on tuesday. i'm expecting the company will give a good number.
BOOM is been trading in rectangle pattern for sometime now, the 52 week high is 26.25 is not too far away from the close last friday @ 25.50. i have a feeling BOOM will reach new high on tuesday morning. happy trading ;)
Dynamic Materials Sets Date for Third Quarter Earnings Announcement:
BOULDER, Colo., Oct. 25 /PRNewswire-FirstCall/ -- Dynamic Materials Corporation (DMC) (Nasdaq: BOOM - News), the world's leading provider of explosion-welded clad metal plates and associated services, today announced that it intends to issue its third quarter financial results before the stock market opens on Tuesday, November 8, 2005.
3) Stock Chart:
1) SMTX (SMTC CORP)
2) A former 3sof pick. Company swung to a profit from a loss last quarter. Started a restructuring, refinancing, and a new focus on operations in 2004. Management is focused on improving the balance sheet, paying down debt, and improving growth and profitability.
Reports earnings on November 14. If results are as management predicted, then they should post another profitable quarter. Hopefully SANM's earnings preview things to come for SMTX's upcoming quarter.
Technically, stock has held steady above 2.10 after the last breakout. New to TA, but seems to have broken out of a descending wedge and has slowly trended higher in anticipation of earnings. Stock could double from current levels if earnings are good.
Profile: SMTC Corporation provides electronics manufacturing services to original equipment manufacturers (OEMs) primarily in North America, Europe, Asia, and Mexico. Its services comprise product development, which include product design, prototyping, and qualification testing; product assembly and test services; and interconnect, which consists of design, development, and manufacture of interconnect assemblies, such as optical and electrical cable and harness assemblies. The company also offers sheet metal fabrication services used in the assembly of a range of electronic enclosures. It offers its services to OEMs in the industrial, enterprise computing and networking, and communications sectors.
SIRIUS Sat Radio Ticker SIRI
I think the market is underestimating the loyalty of the average Howard Stern Listener.
He will be off regular radio and will be exlusively on Sirius starting in Jan, milions of new subscribers will follow.
My pick is CNXT - Conexant Systems
Conexant is another 3SOF pick, and quite frankly (having posted quite late before the beginning of the competition) I'm amazed no-one beat me to it ::)
Conexant just broke out of a major ascending triangle pattern, which has been building for the last 6 months after hitting all time lows under 1.00 in May. The technical target of this ascending triangle breakout is around 2.95, but what really interests me about this chart is the huge gap that can be seen on the 2 year chart, when CNXT gapped down from over $4 to $2.60 over the 4th of July weekend in 2004 (can't have been a nice holiday for shareholders that one :'(). Now CNXT is riding high on this breakout wave at present, and while analysts and some guy named Cramer think it should reach 2.50, I have a sneaking suspicion thatt it could run much higher. 2.50 is real close to the bottom of that huge gap, and I think that if it can break that key level in the next couple of weeks, it could really run.
Every tecchnical indicator and analysis site I could find (e.g. http://www.stockta.com/cgi-bin/analysis.pl?symb=CNXT&num1=3&cobrand=&mode=stock) shows CNXT as being extremely bullish, and confirms that this breakout is for real (but you just need to look at the chart to figure that one out).
Fundamentally, (and I don't know too much about it on this side), CNXT recently reported better-than-expected earnings, beating concesus estimates of a 2c a share loss, and showing that they returned to profitability a quarter earlier than anticipated. This bodes well for them, and clearly shows that their turnaround strategy is producing results. I think that this move is set to continue, and with further strengthening, could very well return to the level it held in the first half of 2004.
Satcon Tech SATC
SatCon Technology Corporation engages in the design, development, manufacture, and marketing of power and energy management products for digital power markets worldwide. The company operates in three segments: Power Systems, Electronics, and Applied Technology. The Power Systems segment offers power solutions, shaker vibration test systems, magnetic levitation systems, industrial automation motors, rotary uninterruptible power supply systems, machine tool motors, and power conditioning systems.
With ongoing war in IRAQ and instability in many regions of the world this is a small growing concern that manufacturers demand power use items for the military.. The share price is becoming mor attractive to institutions and I see that increasing. The stock price is now bouncing off a double bottom and I see the possibility of a double in the next 30 days..
Ticker:
SATC
I tried copying but with no luck off of stock charts.. Can someone go in and add the chart to my post? Thanks in advance..
http://stockcharts.com/h-sc/ui
My pick is GTE
OK I'm pissed off because I just spent a half hour typing up a long essay about my pick and then when I clicked "post" I got the error message "file size too big" because of the chart picture I had tried to attach. I clicked the link I was provided to return to my message and everything I had typed was gone. So I will type a SHORT summary because I have to get to bed.
Technicals: Broke descending trendline in mid-Oct. Rallied from $1.60 (trendline b.o. point) to high of $2.40 b4 retracing to current pps 1.80's. Consolidation pattern = Bullish flag . 20ema/center BB at 1.82. With Friday close @ 1.87, we are right near a good entry point IMO. Another 50% move like the 1.60-2.40 move is what I'd like to see. 200 sma is just north of 2.80 and that's my target.
Fundamentals: Nothing compelling here. They pay $1 for every $1 of revenue. Throwback to the dot-bomb era. What drives this stock is news about their Stratellite program. The Stratellite is an airship kinda like a blimp that theoretically could hover in the stratosphere and serve a a giant telecommunications hub for a large state or a small country. News is unpredictable, but I sure would appreciate some news in the next 3 weeks to give me a shot at winning this contest!
So I checked my chart size and it is 131 kb, which is 3 kb more than the limit. Unbelievable. My last post got destroyed b/c of 3 kilobytes???? I don't know whether to LOL or COL (cry out loud). Since I have no idea how to shave 3 kilobytes off a picture I will just have post a link --> http://tinyurl.com/9ktey
Thanks and GO GTE!!!!
Luke Q
Warning – spoiler below (put there due to suggestions in rules)
Pick MII - MicroIslet, Inc
When this contest was announced there was plenty of time so I did not give it much thought and forgot about it until this morning seeing the email about it. There is only a couple of hours and it is daytime here and I have things to do so not so much time to pick.
Well – a lot of stocks doubled or more in the last month and you have to figure that many will do it this month also. Whether one of the picks here will double or more is not known but I must for the sake of competition figure at least one of the picks will do 50-100% so how can I find a stock that can do that in the next few minutes? I can't in all likelihood but I ought to go on the board with something just for the sport of it.
I looked at MII a biotech that has been playing 50-200 pinball in the last month bouncing between those two EMAs and now at the trend line also so has decent odds it will break higher and maybe test its 2.80 recent high but that is only a 40% move if it works and it has yet to break above the trend.
So instead lets for fun use a similar symbol for the pick XXXXXXXXXXXXXXX
Delete delete delete
Oh oh --- I had my whole piece written on a stock but then checked rules on another matter and see I cannot use it as it is now under $1. Shucks.
Now I really have no time so to do something I may as well put in MII as it is trading at $2 even and has an averge volume of 105k shares so meets the criteria. The problem is I cannot see anything major to move it up 100% in a month but let's see if we can get it at least to break above the trend line and maybe try for the September high.
Here is what MoneyCentral says about them:
MicroIslet, Inc. is a biotechnology company engaged in the research, development and commercialization of technologies in the field of transplantation therapy for people with insulin-dependent diabetes. The Company's islet transplantation technology, licensed from Duke University, includes methods for isolating, culturing, cryopreservation and immuno-protection (microencapsulation) of islet cells. MicroIslet intends to seek United States Food and Drug Administration (FDA) approval for and bring to market a first product called MicroIslet-P, which will be an injectable suspension of microencapsulated porcine islet cells for the treatment of insulin-dependent diabetes. MicroIslet-P is intended to be administered into the patient's abdominal cavity, where the transplanted islet cells will produce insulin in response to increases in blood glucose, much like the patient's original pancreatic islet cells that have been destroyed by disease.
----------
They have no sales or income but they have hope. In October they get a three-year $1.7 million grant from National Institutes of Health. As it is 3 year maybe nothing will happen too soon but I do not have long to submit this. The stock held on the pullback both time at the 200-day EMA and this is also the 62% retrace so pretty good support.
Unless I really plan to get into a stock to hold for many months or years I try not to do to much research and instead rely charts as for me knowing too much about a company can keep me in the stock even if the charts tell me to get out.
Maybe next time I will take some time to find a better one but this at least has support not far away so a stop loss could be but under there and the chart is decent.
I hope all have fun and make money on their picks.
(http://xs54.xs.to/pics/05451/mii0411.jpg)
Here is a link to a live chart of it so you can track the fantastic gains over the coming month
http://tinyurl.com/7w44q
(Lucas - as a long shot I also thought of GTE as if their blimp ever gets off the ground the price could do the same. I only while writing see your post below - hope it does well)
AXYX - AXONYX INC. that´s my pick for the next month
Something about AXYX:
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders. The Company currently has three compounds in development for Alzheimer's disease, namely Phenserine - a potential symptomatic and disease progression treatment of mild to moderate Alzheimer's Disease (AD), Posiphen(TM) - a potential disease progression treatment for AD and BisNorCymcerine (BNC) - a potential symptomatic treatment of severe AD.
My opinion to AXYX:
massive undervalued, have a look to their cash position. Hope we hear some news after the roadshow...
The chart: ... not very friendly..
(http://bigcharts.marketwatch.com/charts/big.chart?symb=axyx&compidx=aaaaa%3A0&ma=0&maval=9&uf=0&lf=4&lf2=32&lf3=2&type=4&size=1&state=8&sid=127329&style=330&time=7&freq=1&comp=NO%5FSYMBOL%5FCHOSEN&nosettings=1&rand=6236&mocktick=1)
Ok, time out to submit your pick for the «3StocksonFire $1000 Stock Picking Contest».
Thanks to all for your participation, on the 5th of December we'll know who the winner is :D
Now I'll lock this post. Everybody can continue discussing the contest and picks on this board, using other threads.
Thank you !